Alchemab Therapeutics has raised $80m to advance research originating at University of Oxford, Johns Hopkins University and Mount Sinai Hospital.
Alchemab Therapeutics, a UK-based developer of antibody therapies that is based on research at University of Oxford, Johns Hopkins University and Mount Sinai Hospital, has collected £60m ($82m) in series A financing.
RA Capital Management led the round, which also included Lightstone Ventures, Data Collective VC, DHVC, SV Health Investors and Dementia Discovery Fund.
Founded in 2019, Alchemab is working on a target-agnostic drug discovery platform that analyses the antibody repertoires of patients who exhibit an unexpected resistance…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.